Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 12/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20607355 | 0.84 | ERN1 (0.45) | ERN1PTGS1PTGS2ALOX5ALDH1A1 | |
| SCHEMBL20607061 | 0.82 | ERN1 (0.44) | ERN1PTGS1PTGS2ALOX5ALDH1A1 | |
| SCHEMBL27452224 | 0.78 | ERN1 (0.52) | ERN1CA1CA2ALDH1A1TSHR | |
| SCHEMBL16221828 | 0.78 | ERN1 (0.52) | ERN1CA1CA2ALDH1A1TSHR | |
| SCHEMBL27867837 | 0.76 | ERN1 (0.45) | ERN1CA1CA2 | |
| SCHEMBL13494914 | 0.76 | ERN1 (0.54) | ERN1 | |
| SCHEMBL30645199 | 0.76 | ERN1 (0.54) | ERN1 | |
| SCHEMBL5366778 | 0.76 | ALDH1A1 (0.39) | ERN1ALDH1A1TSHR | |
| SCHEMBL29952775 | 0.75 | ERN1 (0.64) | ERN1PTGS1PTGS2ALOX5 | |
| SCHEMBL15783650 | 0.75 | ERN1 (0.48) | ERN1PTGS1PTGS2ALOX5CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | FEN1, ERCC4, DCLRE1B | ERN1 258/4885PTGS1 1239/4885PTGS2 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.